Previously, RSK2 has been reported to be activated or upregulated through PIM in FLT3-ITD-positive AML cells, and suggested to be required for leukemogenesis by FLT3-ITD but not by BCR/ABL [17,18]. Here, RPS6KA3 is linked to acute myeloid leukemia.